Insight Molecular Diagnostics’ (IMDX) Neutral Rating Reiterated at BTIG Research

BTIG Research reaffirmed their neutral rating on shares of Insight Molecular Diagnostics (NASDAQ:IMDX – Free Report) in a research report sent to investors on Wednesday morning, MarketBeat.com reports.

IMDX has been the subject of several other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insight Molecular Diagnostics in a research note on Monday, September 21st. Wall Street Zen lowered shares of Insight Molecular Diagnostics from a “hold” rating to a “sell” rating in a report on Saturday, October 3rd. Needham & Company LLC restated a “buy” rating and set a $9.00 price objective on shares of Insight Molecular Diagnostics in a research report on Tuesday, August 18th. Finally, Stephens reaffirmed an “equal weight” rating and set a $4.00 price objective on shares of Insight Molecular Diagnostics in a report on Wednesday. Two analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $5.75.

Read Our Latest Stock Report on IMDX

Insight Molecular Diagnostics Stock Up 17.5%

NASDAQ:IMDX opened at $1.95 on Wednesday. Insight Molecular Diagnostics has a 52 week low of $1.50 and a 52 week high of $7.51. The stock has a market capitalization of $63.80 million, a PE ratio of -1.56 and a beta of 1.90. The stock’s 50-day moving average price is $3.05 and its 200-day moving average price is $4.43.

Insight Molecular Diagnostics (NASDAQ:IMDX – Get Free Report) last released its quarterly earnings results on Monday, November 16th. The company reported ($0.19) earnings per share for the quarter. The company had revenue of $0.56 million during the quarter.

Insider Activity at Insight Molecular Diagnostics

In other news, major shareholder Broadwood Partners, L.P. purchased 3,428,571 shares of the company’s stock in a transaction that occurred on Tuesday, November 17th. The stock was purchased at an average cost of $1.75 per share, for a total transaction of $5,999,999.25. Following the completion of the transaction, the insider owned 16,113,455 shares of the company’s stock, valued at $28,198,546.25. This trade represents a 27.03% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 2.21% of the company’s stock.

Insight Molecular Diagnostics Company Profile

(Get Free Report)

Oncocyte Corporation, now known as Insight Molecular Diagnostics, Inc. (NASDAQ: IMDX), is a molecular diagnostics company focused on monitoring organ transplants. Its tests analyze donor-derived cell-free DNA in a transplant recipient’s blood to help assess graft health and identify signs of potential injury or rejection. The company’s VitaGraft tests include assays for kidney and liver transplant monitoring. These laboratory-developed tests are processed through the company’s clinical laboratory and are intended to provide clinicians with information that can complement other aspects of post-transplant care.

Further Reading

Analyst Recommendations for Insight Molecular Diagnostics (NASDAQ:IMDX)

Receive News & Ratings for Insight Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insight Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.